Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKTX NASDAQ:AYTU NASDAQ:DYAI NASDAQ:VIRI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKTXAkari Therapeutics$3.89-24.5%$6.35$3.25▼$56.80$4.44M0.6423,955 shs35,504 shsAYTUAytu BioPharma$2.30-5.8%$2.59$1.26▼$3.07$24.67M0.2864,799 shs89,747 shsDYAIDyadic International$0.75+3.3%$0.82$0.65▼$1.35$27.26M1.1864,900 shs14,607 shsVIRIVirios Therapeutics$1.69+2.4%$2.23$0.13▼$1.04$32.55M1.581.05 million shs91,072 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKTXAkari Therapeutics-17.60%-5.85%+34.46%-46.82%-89.78%AYTUAytu BioPharma-2.40%-6.51%-4.31%+5.63%+95.20%DYAIDyadic International-5.52%-8.33%-18.70%-13.05%-32.32%VIRIVirios Therapeutics0.00%+13.01%-17.09%-44.07%-63.82%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKTXAkari Therapeutics$3.89-24.5%$6.35$3.25▼$56.80$4.44M0.6423,955 shs35,504 shsAYTUAytu BioPharma$2.30-5.8%$2.59$1.26▼$3.07$24.67M0.2864,799 shs89,747 shsDYAIDyadic International$0.75+3.3%$0.82$0.65▼$1.35$27.26M1.1864,900 shs14,607 shsVIRIVirios Therapeutics$1.69+2.4%$2.23$0.13▼$1.04$32.55M1.581.05 million shs91,072 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKTXAkari Therapeutics-17.60%-5.85%+34.46%-46.82%-89.78%AYTUAytu BioPharma-2.40%-6.51%-4.31%+5.63%+95.20%DYAIDyadic International-5.52%-8.33%-18.70%-13.05%-32.32%VIRIVirios Therapeutics0.00%+13.01%-17.09%-44.07%-63.82%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKTXAkari Therapeutics 2.25Hold$89.002,187.92% UpsideAYTUAytu BioPharma 2.20Hold$9.33305.97% UpsideDYAIDyadic International 2.33Hold$3.00301.07% UpsideVIRIVirios Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest AKTX, AYTU, DYAI, and VIRI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/20/2026AKTXAkari Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/8/2026AYTUAytu BioPharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/8/2026AKTXAkari Therapeutics Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold4/1/2026AKTXAkari Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$27.003/31/2026AYTUAytu BioPharma Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell3/27/2026DYAIDyadic International Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/2/2026AYTUAytu BioPharma Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKTXAkari TherapeuticsN/AN/AN/AN/A$24.75 per shareN/AAYTUAytu BioPharma$66.38M0.37$0.35 per share6.66$2.11 per share1.09DYAIDyadic International$3.09M8.82N/AN/A$0.03 per share24.93VIRIVirios TherapeuticsN/AN/AN/AN/A$0.20 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKTXAkari Therapeutics-$17.30MN/AN/AN/AN/AN/A-70.34%-35.46%N/AAYTUAytu BioPharma-$13.56M-$3.84N/A7.66N/A-39.02%-28.22%-5.20%5/13/2026 (Estimated)DYAIDyadic International-$7.36M-$0.25N/AN/AN/A-239.67%-695.96%-78.24%5/13/2026 (Estimated)VIRIVirios Therapeutics-$5.30M-$0.27N/AN/AN/AN/A-130.33%-115.00%N/ALatest AKTX, AYTU, DYAI, and VIRI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q3 2026AYTUAytu BioPharma-$0.4433N/AN/AN/A$12.05 millionN/A5/13/2026Q1 2026DYAIDyadic International-$0.04N/AN/AN/A$0.90 millionN/A3/30/2026Q4 2025AKTXAkari Therapeutics-$0.03-$2.68-$2.65N/AN/AN/A3/25/2026Q4 2025DYAIDyadic International-$0.03-$0.06-$0.03-$0.06$1.34 million$0.57 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAKTXAkari TherapeuticsN/AN/AN/AN/AN/AAYTUAytu BioPharmaN/AN/AN/AN/AN/ADYAIDyadic InternationalN/AN/AN/AN/AN/AVIRIVirios TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKTXAkari TherapeuticsN/A0.440.44AYTUAytu BioPharma0.701.161.03DYAIDyadic International4.082.682.68VIRIVirios TherapeuticsN/A7.277.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKTXAkari Therapeutics5.06%AYTUAytu BioPharma33.49%DYAIDyadic International27.95%VIRIVirios Therapeutics9.05%Insider OwnershipCompanyInsider OwnershipAKTXAkari Therapeutics30.70%AYTUAytu BioPharma4.90%DYAIDyadic International29.50%VIRIVirios Therapeutics12.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKTXAkari Therapeutics91.14 million793,000Not OptionableAYTUAytu BioPharma16010.73 million10.21 millionNot OptionableDYAIDyadic International736.44 million25.69 millionOptionableVIRIVirios Therapeutics519.26 million16.91 millionNo DataAKTX, AYTU, DYAI, and VIRI HeadlinesRecent News About These CompaniesHead to Head Survey: Orgenesis (NASDAQ:ORGS) vs. Virios Therapeutics (NASDAQ:VIRI)May 11 at 3:51 AM | americanbankingnews.comVirios Therapeutics (NASDAQ:VIRI) Trading Down 3.4% - What's Next?May 6, 2026 | americanbankingnews.comDigital acceptance and commitment therapy for fibromyalgia – Authors' replyJune 13, 2025 | thelancet.comTDogwood Therapeutics Inc (DWTX)March 16, 2025 | investing.comDogwood prices 578,950 shares at $8.26 in registered direct offeringMarch 13, 2025 | markets.businessinsider.comDogwood announces conversion of existing $19.5M in debt to equityMarch 12, 2025 | markets.businessinsider.comDWTX Stock trading resumesFebruary 11, 2025 | markets.businessinsider.comDogwood Therapeutics, Inc. (DWTX)February 2, 2025 | finance.yahoo.comDWTX Stock trading halted, volatility trading pauseJanuary 28, 2025 | markets.businessinsider.comDWTX Stock Hits 52-Week High at $15.74 Amidst Strong Yearly GrowthJanuary 23, 2025 | msn.comDogwood announces first patient dosed in Phase 2b trial on HalneuronJanuary 21, 2025 | markets.businessinsider.comPolluted communities hold their breath as companies struggle with California’s diesel truck banDecember 10, 2024 | apnews.comADogwood Therapeutics faces potential Nasdaq delistingNovember 23, 2024 | uk.investing.comDogwood says low-dose IMC-2 treatment reduces long-COVID fatigueNovember 18, 2024 | markets.businessinsider.comDogwood Study Finds IMC-2 Treatment Reduces Long-COVID Related Fatigue, Sleep DisturbanceNovember 18, 2024 | markets.businessinsider.comInovio Pharmaceuticals (NASDAQ:INO) Stock Quotes, Forecast and News SummaryNovember 16, 2024 | benzinga.comDWTX: Phase 2 Long COVID Results Expected SoonNovember 12, 2024 | msn.comBuy Rating for Dogwood Therapeutics: Strategic Initiatives and Promising Pipeline Drive Analyst ConfidenceNovember 10, 2024 | markets.businessinsider.comDogwood Therapeutics Reports Q3 2024 Financial ResultsNovember 9, 2024 | markets.businessinsider.comDogwood Therapeutics Announces Third Quarter 2024 Financial ResultsNovember 8, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAKTX, AYTU, DYAI, and VIRI Company DescriptionsAkari Therapeutics NASDAQ:AKTX$3.89 -1.26 (-24.47%) As of 11:52 AM Eastern This is a fair market value price provided by Massive. Learn more.Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.Aytu BioPharma NASDAQ:AYTU$2.30 -0.14 (-5.78%) As of 11:54 AM Eastern This is a fair market value price provided by Massive. Learn more.Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.Dyadic International NASDAQ:DYAI$0.75 +0.02 (+3.29%) As of 11:51 AM Eastern This is a fair market value price provided by Massive. Learn more.Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.Virios Therapeutics NASDAQ:VIRI$1.69 +0.04 (+2.42%) As of 05/11/2026Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Sony's $4 Billion Bet on Rock & Roll Royalties Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It AI Demand Fuels Strong Q1 Earnings for Constellation Energy TMC Forges a New EV Supply Chain at the Bottom of the Sea MercadoLibre Boldly Invests in Growth: Discount Deepens Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader 5 Stocks Positioned to Benefit From the AI Inference Boom Sell in May and Go Away—Starting With These 3 Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
